Valuation: Sangamo Therapeutics, Inc.

Market Cap 66.29M 56.81M 53.14M 48.59M 91.69M 6.35B 92.66M 629M 245M 3.19B 249M 243M 10.55B P/E 2024
-2.1x
P/E 2025 -0.96x
Enterprise Value 72.13M 61.82M 57.83M 52.87M 99.77M 6.91B 101M 684M 266M 3.47B 271M 265M 11.48B EV / Sales 2024
3.49x
EV / Sales 2025 3.72x
Free-Float
99.07%
Yield 2024 *
-
Yield 2025 -
1 day+12.44%
1 week-4.93%
Current month+118.58%
1 month+146.15%
3 months-8.21%
6 months-66.14%
Current year-61.90%
1 week 0.13
Extreme 0.1322
0.17
1 month 0.06
Extreme 0.06
0.2
Current year 0.03
Extreme 0.03
0.6
1 year 0.03
Extreme 0.03
0.77
3 years 0.03
Extreme 0.03
3.18
5 years 0.03
Extreme 0.03
11.49
10 years 0.03
Extreme 0.03
27.5
Manager TitleAgeSince
Chief Executive Officer 63 2016-05-31
Director of Finance/CFO 47 2026-02-02
Chief Tech/Sci/R&D Officer - 2023-11-16
Director TitleAgeSince
Chairman 70 2017-05-31
Director/Board Member 63 2016-05-31
Director/Board Member 68 2016-05-31
Date Insider Type Main position Quantity % Market Cap.
2/24/26 Tax

Executive/Senior Manager

14,417 0.0043%
2/24/26 Tax

Chief Technology Officer

5,951 0.0018%
2/24/26 Tax

Chief Executive Officer

38,928 0.0116%
Change 5-day change 1-year change 3-year change Capi.($)
+12.44%-4.93%-72.71%-81.82% 58.95M
-4.31%-6.62%+65.79%+98.02% 72.12B
-4.19%+1.05%+52.79%+85.53% 65.85B
-3.22%+23.17%+1.75%-5.23% 29.28B
-1.42%-3.38%-5.99%+465.34% 27.47B
+4.32%+4.26%+52.19%+14.21% 26.7B
-1.81%+0.38%+34.52%-18.33% 20.06B
+5.36%+4.61%+270.18%+415.10% 18.22B
-0.57%-3.78%+11.11%+517.39% 16.4B
+0.87%+4.26%+41.21%+150.80% 13.4B
Average +0.77%+4.33%+45.08%+164.10% 28.96B
Weighted average by Cap. -1.85%+3.12%+54.73%+149.91%

Financials

2024 2025
Net sales 57.8M 49.53M 46.34M 42.37M 79.95M 5.53B 80.8M 548M 213M 2.78B 217M 212M 9.19B 39.55M 33.9M 31.71M 28.99M 54.71M 3.79B 55.29M 375M 146M 1.9B 149M 145M 6.29B
Net income -97.94M -83.94M -78.52M -71.79M -135M -9.38B -137M -929M -361M -4.71B -368M -360M -15.58B -123M -105M -98.56M -90.11M -170M -11.77B -172M -1.17B -453M -5.91B -462M -452M -19.56B
Net Debt -11.35M -9.73M -9.1M -8.32M -15.7M -1.09B -15.87M -108M -41.88M -546M -42.62M -41.7M -1.81B 5.85M 5.01M 4.69M 4.29M 8.09M 560M 8.17M 55.47M 21.57M 281M 21.95M 21.48M 930M
Logo Sangamo Therapeutics, Inc.
Sangamo Therapeutics, Inc. is a genomic medicine company. The Company’s zinc finger (ZF) epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic needs. Its pipeline includes Chronic Neuropathic Pain - ST-503 and Isaralgagene civaparvovec (ST-920). ST-503 is an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain. ST-920 is a wholly owned gene therapy product candidate for the treatment of Fabry disease.
Employees
142
Date Price Change Volume
26-08-24 US$0.1600 +12.44% 2,706,299
26-08-21 US$0.1423 -11.17% 5,486,587
26-08-20 US$0.1602 -0.50% 1,704,868
26-08-19 US$0.1610 +0.94% 1,994,671
26-08-18 US$0.1595 -5.23% 3,868,733
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SGMOQ Stock